New antiproliferative 1,3,4-oxadiazole/benzimidazole derivatives: Design, synthesis, and biological evaluation as dual EGFR and BRAFV600E inhibitors
Bioorganic Chemistry · 2025-04 · 157 · 108297
DOI: 10.1016/j.bioorg.2025.108297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025-04. Verfasst von Fatma Fouad Hagar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Oxadiazoles, Benzimidazoles, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
A new series of benzimidazole-oxadiazole-small molecules were synthesized and confirmed with various spectroscopic techniques. The prepared derivatives exhibited significant inhibitory activity against the proliferation of different cancer cells. The benzimidazoles 10f, 10 h, 10 g, and 10i showed broad anticancer activity with no selectivity in five-dose assays. All prepared compounds displayed potent inhibitory activity against proliferation of a panel of four human cancer cells (HT-29, Panc-1, MCF-7, and A-549) with IC50 values ranging from 24 nM to 80 nM and with significant safety profile against MCF-10 A normal cells. According to the mechanistic study, the most potent compounds (9a, 9b, 10e, 10f, & 10i) displayed remarkable inhibitory effectiveness against EGFR and BRAFV600E and were more potent than reference drugs erlotinib and vemurafenib. Molecular docking study for compounds 9a, 9b, 10e, 10f, and 10i agreed with mechanistic results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
- Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. Electronic address: samar_hafez@mu.edu.eg.
- Department of Pharmacognosy, Faculty of Pharmacy, Nahda University, 62513 Beni-Suef, Egypt; Department of Pharmacognosy, Collage of Pharmacy, Almaaqal University, 61014 Basrah, Iraq.
- Pharmacology Department, College of Pharmacy, Jouf university, Sakaka, Aljouf 72341, Saudi Arabia.
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
- Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt; Raabe College of Pharmacy, Ohio Northern University, OH, USA.
Förderung
- National Cancer Institute
Zitieren
APA
Hagar, F. F., Abbas, S. H., Sayed, A. M., Gomaa, H. A. M., Youssif, B. G. M., Abdelhamid, D., & Abdel-Aziz, M. (2025). New antiproliferative 1,3,4-oxadiazole/benzimidazole derivatives: Design, synthesis, and biological evaluation as dual EGFR and BRAFV600E inhibitors. Bioorganic Chemistry, 157, 108297. https://doi.org/10.1016/j.bioorg.2025.108297
Vancouver
Hagar FF, Abbas SH, Sayed AM, Gomaa HAM, Youssif BGM, Abdelhamid D, et al. New antiproliferative 1,3,4-oxadiazole/benzimidazole derivatives: Design, synthesis, and biological evaluation as dual EGFR and BRAFV600E inhibitors. Bioorganic Chemistry. 2025;157:108297. doi:10.1016/j.bioorg.2025.108297
BibTeX
@article{Hagar2025,
author = {Hagar, Fatma Fouad and Abbas, Samar H and Sayed, Ahmed M and Gomaa, Hesham A M and Youssif, Bahaa G M and Abdelhamid, Dalia and Abdel-Aziz, Mohamed},
title = {New antiproliferative 1,3,4-oxadiazole/benzimidazole derivatives: Design, synthesis, and biological evaluation as dual EGFR and BRAFV600E inhibitors},
journal = {Bioorganic Chemistry},
year = {2025},
volume = {157},
pages = {108297},
doi = {10.1016/j.bioorg.2025.108297}
}
EUVIMED